## Transgenic Rabbits for Human Disease Models  
Transgenic rabbits as human disease models [47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57; 58; 59; 60; 61; 62; 63; 64; 65; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 101; 102; 103; 104; 105; 106; 107; 108; 109; 110; 111; 111; 1112; 113; 114; 115] are listed in Table 2. \begin{table}
\begin{tabular}{l l l} \hline \hline
**Possible Disease Models/Transgene** & **Remarks** & **Ref.** \\ \hline \hline
**Lipid metabolism and atherosclerosis** & & [47] \\ \hline Human apo(a) & & [48] \\ Human apo(a) and apoB & & [49; 50] \\ Human apoA-I-Vc-III/A-IV gene cluster & & [51] \\ Human apoA-II & & [52] \\ Human apoB & & [53] \\ Human apoB-100 & & [54] \\ Human APOBECEC1 & & [55] \\ Rabbit apdepee-shRNA & RNA-1 knockdown of rabbit APOBEC1 & [56] \\ Human apoC-III & Knockout was also produced [27] & [57] \\ Human apoE2 & Knockout was also produced [25; 26] & [58] \\ Human apoE3 & & [59; 60] \\ Human CETP & Knockout was also produced [22] & [61] \\ Human CRP & & [62] \\ Human EL & & [63; 64] \\ Human HL & & [65; 66] \\ Human LCAT & & [67; 68] \\
15-Lipoxygenase type 1 & Osteoporosis and periodontal disease [69; 70] & [71] \\ Human LPL & Obesity [72] & [73; 74] \\ Rabbit MMP-1 & & [75] \\ Human MMP-9 & & [76] \\ Human MMP-12 & Inflammation [77] & [78] \\ Human PLTP & & [79] \\ Human Urotensin II & & [80] \\ \hline
**Cardiac failure** & & \\ \hline \hline
**Hypertrophic cardiomyopathy/cardiac protein** & & [81; 82; 83; 84] \\ \hline Rabbit \(\alpha\)-MyHC & & [85] \\ \hline Rabbit cThI-G146 mutation & & [86] \\ \hline Rabbit Cardiac Csca & & [86; 87] \\ \hline Rabbit ELC1v-M149V mutation & & [88] \\ \hline Rabbit Phospholamban & & [89] \\ \hline Human \(\beta\)-MyHC-R403Q mutation & & [90] \\ \hline Rabbit \(\beta\)-MyHC-R403 mutation & & [91; 92] \\ \hline Ry2R R4497C & & [93] \\ \hline \hline
**Proarrhyth** & & \\ \hline Human KVLQT1-Y315S mutation (LQT1) & Long QT syndrome & [94; 95] \\ \hline Human HERG-G628S mutation (LQT2) & & [96; 97] \\ \hline
**Immunology** & & \\ \hline Human HLA-A2.1 & Immunity to viral infection & [98] \\ \hline Rabbit FcRn & Humoral immune response & [99] \\ \hline Rabbit lPfI & B cell-deficient (B cell development) & [100] \\ \hline Human CD4 & AIDS & [101; 102; 103] \\ \hline Human CD5 and CD59 & Xenotransplantation & [104] \\ \hline
**Tumor (oncogenesis)** & & \\ \hline Rabbit EJ-ras DNA & Papilloma, keratoacanthomas and squamous cell carcinoma & [105; 106] \\ \hline Rabbit c-myc oncogene & Lymphocytic leukemia & [107] \\ \hline Rabbit E-x-myc oncogene & Lymphoid tumor & [108] \\ \hline
**Other models** & & \\ \hline Bovine GH & Acromegaly and diabetes mellitus & [109] \\ \hline EGFP & Marker for tissue engineering and regenerative medicine & [110] \\ \hline O44 promoter-EGFP & Marker to investigate rabbit embryo development & [111] \\ \hline Ovine PrP & Rabbits are susceptible to a various prion isolates [116]. & [112] \\ \hline Rabbit Rhodopsin-P34/TL mutation & Retinitis pigmentosa & [113] \\ \hline Human VEGF & Hepatic hemangioma (Kasabach-Merritt syndrome), & [114; 115] \\ \hline \hline \end{tabular}  
* APOBEC1, APOB mRNA editing protein; CETP, cholesteryl ester transfer protein; CRP, C-reactive protein; EL, endothelial Lipase; HL, hepatic lipase; LCAT, lecithin: cholesterol acyltransferase; LPL, LPL, lipoprotein lipase; MMP, matrix metalloproteinase; PLTP, plasma phospholipid transfer protein; MyHC, myosin heavy chain; cTnI, cardiac troponin I; ELCLv, essential myosin light chain 1; RyR2, cardiac yyanodine receptor. HLA, human leukocyte antigens; FcRn, neonatal Fc receptor; GH, growth hormone; EGFP, enhanced green fluorescent protein; PrP, prion related protein; VEGF, vascular endothelial growth factor.  
\end{table} 
Table 2: Transgenic rabbits for human disease models. The most-used research areas of transgenic rabbits as human disease models are lipid metabolism and atherosclerosis.